EXPLORANCE
1.10.2018 07:02:05 CEST | Business Wire | Press release
Explorance, the leading provider of Learning Journey Analytics (LJA) solutions doubled its European client base in the past year. With the opening of new European offices, Explorance will be able to better partner with its growing European clients.
Improving the quality and relevance of teaching and learning in the European higher education market is the centre of the Bologna Process. The Yerevan Communiqué strengthened the call for better visibility of this policy area. According to the EUA Trends 2018 survey, 90% of the institutions use student feedback surveys to assess and enhance the quality of teaching. As the Bologna Process entices institutions to embrace a digitally-enabled approach, more institutions move toward the strategic use of digital tools to measure learning and teaching improvements.
“Before implementing Blue, we were using a dozen or so traditional questionnaires, combined with a few digital surveys. The wide range of individual solutions made it impossible to take full benefit of course evaluations,” says Mustapha Ali El-Ahmad, Senior Evaluation Consultant and Analyst at the Aarhus University. He adds, “Blue combines all these different questionnaires into one single solution, cleaning the data from the LMS & SIS, and automating the data analysis, while accommodating to different schools’ requirements.” Explorance’s Blue is built to support various feedback processes including course evaluations, competency development assessment, midterm reviews, applicant feedback, alumni perception analysis, student satisfaction, organisational surveys, and 360 degree reviews.
“The surge in demand for Explorance software and services in Europe indicates a growing need for proven online teaching and learning evaluation tools and increased trust in the Blue solution,” commented Ian Haugh, General Manager of the European offices. The new European office is located in Amsterdam and coordinates local activities across Europe and the UK. Local professional services are offered across Europe and customer service is provided 24/7 in multiple languages.
Blue surveys and evaluation solutions are fully localised with English, French, Spanish, German, Dutch, Swedish, Norwegian, Danish, Icelandic, Italian, Russian and Portuguese support. To support student mobility, Blue allows multiple languages to be used in one implementation at the same time. For an evaluation of your organisation’s needs, contact Explorance for a demonstration .
About Explorance
Explorance is a Learning Journey Analytics (LJA) provider that supports organisations in making the right decisions using fact-based feedback data. Through its Blue suite of products, organisations can assess needs, expectations, competencies, and monitor improvement over time.
Founded in 2003, Explorance is a privately held corporation headquartered in Montreal, Canada with business units in America, APAC, Europe, and the MENA region. As of 2014, Explorance has been ranked top employer by the Great Places to Work Institute®. Explorance's clients span a wide variety of learning organisations including academia, consulting firms, government institutions, and corporations. Learn more about Explorance .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180930005020/en/
Contact:
Gil Gruber gil@directobjective.com +1.514.238.7766
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom